Writing group disclosures: conflicts of interests and relationships with industry
| WG ‘expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| WG member | Employment | Research grant (current) | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
| Category A (chair, co-chair) | ||||||||
| Georg Hansmann (Chair of WG) | Hannover Medical School, Germany | DFG (4348/2-1)*, Fördergemeinschaft deutsche Kinderherzzentren (W-H-001/2014)*, Stiftung KinderHerz (2511-6-13-011)* | None | None | None | None | None | None |
| Christian Apitz (Co-Chair of WG) | University of Ulm, Germany | Behring-Röntgen-Stiftung (59-0018)*, Stiftung KinderHerz (2511-10-13-001)* | None | None | None | None | None | None |
| Category B (WG members who have no conflicts) | ||||||||
| Philipp Beerbaum | Hannover Medical School, Germany | None | None | None | None | None | None | None |
| Anne Hilgendorff | Ludwig-Maximilians University Giessen | Helmholtz (BMBF)*, DZL (BMBF)* | None | None | None | None | None | None |
| Michael Kaestner | University of Ulm, Germany | None | None | None | None | None | None | None |
| Rainer Kozlik-Feldmann | University Heart Center Hamburg, Germany | None | None | None | None | None | None | None |
| Titus Kuehne | German Heart Center Berlin (DHZB), Germany | DFG (KU1329/10-2)*, BMBF Sysmed2-012*, EU FP7* (Cardioproof, Paedigree) | None | None | None | None | None | None |
| Heiner Latus | University of Gießen, Germany | German Society of Paediatric Cardiology† | None | None | None | None | None | None |
| Ina Michel-Behnke | Medical University Vienna | None | None | None | None | None | None | None |
| Joseph Pattathu | University of Heidelberg, Germany | None | None | None | None | None | None | None |
| Dietmar Schranz | University of Gießen, Germany | Behring-Röntgen-Stiftung*, Deutsche Herzstiftung* | None | None | None | None | None | None |
| Gregor Warnecke | Hannover Medical School, Germany | DFG (SFB 738), DZL (BMBF) | None | None | None | None | None | None |
| Peter Zartner | Deutsches Kinderherz-zentrum, Sankt Augustin, Germany | None | None | None | None | None | European Society of Cardiology | none |
| Category C (WG members who have conflicts) | ||||||||
| Hashim Abdul-Khaliq | Saarland University Medical Center, Germany | None | None | None | None | None | Actelion, Inc.† | None |
| Damien Bonnet | AP-HP, University Paris Descartes, France | Fédération Française de Cardiologie Société Française de Cardiologie | None | Actelion Pharmaceuticals, Pfizer, EliLilly, Bayer | None | None | Actelion Pharmaceuticals, Pfizer, EliLilly, Bayer | None |
| Tero-Pekka Alastalo | University of Helsinki; Blueprint Genetics, Finland | None | None | None | None | Co-founder and co-owner of Blueprint Genetics* | None | None |
| Karl-Otto Dubowy | German Heart Center (HDZ), Bad Oeynhausen, Germany | None | None | Actelion† Bayer Vital† | None | None | None | None |
| Matthias Gorenflo | University of Heidelberg, Germany | None | None | Actelion, Bayer | None | None | Actelion | None |
| Alfred Hager | Deutsches Herzzentrum München (DHM), Germany | None | None | Actelion, Inc.† Pfizer† AOP Orphan† Pharmaceuticals† OMT GmbH† GlaxoSmithKline† Medtronic† Schiller† Abbott† Encysive† | None | Siemens† Gilead† Abbvie† Pfizer† Novartis† Lilly† | Actelion, Inc.† | None |
| Martin Köstenberger | Medical University Graz, Austria | None | None | Actelion, Inc.† | None | None | None | None |
| Juha Koskenvuo | University of Helsinki; Blueprint Genetics, Finland | None | None | None | None | Co-founder and co-owner of Blueprint Genetics* | None | None |
| Astrid Lammers | Münster University Hospital, Germany | Dean's office (15-002) University of Münster | None | None | None | None | Actelion, Inc.† | None |
| Oliver Miera | German Heart Institute Berlin (DHZB), Germany | None | None | Actelion, Inc.†, Pfizer† | None | None | None | None |
| Shahin Moledina | Great Ormond Street Hospital, London, UK | None | None | None | None | None | Bayer† | None |
| Vivek Muthurangu | University College London, UK | None | None | None | None | None | GSK† | None |
This table represents the relationships of WG members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the WG are required to complete and submit. A relationship is considered to be ‘significant’ if (a) the person receives €10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns €10 000 or more of the fair market value of the entity. A relationship is considered to be ‘modest’ if it is less than “significant” under the preceding definition.
*Significant.
†Modest.